Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society

BOULDER, Colo., Oct. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 30th International Annual Congress of the World Muscle Society (WMS). Importantly, the presentations will include a compilation of long-term data of sevasemten in Becker demonstrating sustained disease stabilization compared to natural history. Sevasemten is an orally administered small molecule designed to prevent contraction-induced muscle damage in muscular dystrophies including Becker and Duchenne. The conference will take place at the Austria Centre in Vienna, Austria, October 7-11, 2025. 

Read more at prnewswire.com